Suppr超能文献

减低强度预处理异基因造血移植后高危急性髓系白血病和骨髓增生异常综合征的持续缓解:慢性移植物抗宿主病是改善生存的最强因素。

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

作者信息

Valcárcel David, Martino Rodrigo, Caballero Dolores, Martin Jesus, Ferra Christelle, Nieto Jose B, Sampol Antonia, Bernal M Teresa, Piñana Jose L, Vazquez Lourdes, Ribera Jose M, Besalduch Joan, Moraleda Jose M, Carrera Dolores, Brunet M Salut, Perez-Simón Jose A, Sierra Jorge

机构信息

Hospital de la Santa Creu i Sant Pau, Universitat Autonoma Barcelona, Barcelona, Spain.

出版信息

J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17.

Abstract

PURPOSE

Reduced-intensity conditioning (RIC) for allogeneic stem-cell transplantation (allo-SCT) reduces nonrelapse mortality (NRM). This reduction makes it possible for patients who are ineligible for high-dose myeloablative conditioning allo-SCT to benefit from graft-versus-leukemia reaction. In this multicenter, prospective study of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), we investigated the efficacy of RIC allo-SCT from a human leukocyte antigen-identical sibling by using a regimen that uses fludarabine and busulfan.

PATIENTS AND METHODS

Ninety-three patients with AML (n = 59) and MDS (n = 34) were included, and the median age was of 53 years. Follow-up for survivors was 43 months (range, 3 to 89 months). The conditioning regimen consisted of fludarabine (150 mg/m(2)) and oral busulfan (8 to 10 mg/kg). All except one patient received mobilized peripheral blood stem cells. Graft-versus-host disease (GVHD) prophylaxis consisted of cyslosporine and methotrexate or mycophenolate mofetil.

RESULTS

The 100-day, 1-year, and 4-year incidences of NRM were 8, 16%, and 21%, respectively. The 1- and 4-year relapse cumulative incidences were 23% and 37%, respectively, and leukemia recurrence was the main cause of death. The 4-year disease-free survival (DFS) and overall survival (OS) rates were 43% and 45%, respectively. The 4-year cumulative incidence of chronic GVHD was 53% (45% extensive), and its development was the major factor associated with lower relapse incidence and improved DFS and OS.

CONCLUSION

Our results confirm the capacity of this RIC regimen to obtain long-term remissions in patients ineligible for a conventional allo-SCT. The results suggest an important role of the development of chronic GVHD in reducing relapse and improving DFS and OS.

摘要

目的

异基因干细胞移植(allo-SCT)的减低强度预处理(RIC)可降低非复发死亡率(NRM)。这种降低使得不符合高剂量清髓性预处理allo-SCT条件的患者有可能从移植物抗白血病反应中获益。在这项针对急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)患者的多中心前瞻性研究中,我们使用氟达拉滨和白消安方案,研究了来自人类白细胞抗原相同同胞的RIC allo-SCT的疗效。

患者与方法

纳入93例AML患者(n = 59)和MDS患者(n = 34),中位年龄为53岁。对幸存者的随访时间为43个月(范围3至89个月)。预处理方案包括氟达拉滨(150 mg/m²)和口服白消安(8至10 mg/kg)。除1例患者外,所有患者均接受动员外周血干细胞。移植物抗宿主病(GVHD)预防包括环孢素和甲氨蝶呤或霉酚酸酯。

结果

NRM的100天、1年和4年发生率分别为8%、16%和21%。1年和4年的累积复发率分别为23%和37%,白血病复发是主要死亡原因。4年无病生存率(DFS)和总生存率(OS)分别为43%和45%。慢性GVHD的4年累积发生率为53%(广泛型为45%),其发生是与较低复发率以及改善DFS和OS相关的主要因素。

结论

我们的结果证实了这种RIC方案使不符合传统allo-SCT条件的患者获得长期缓解的能力。结果表明慢性GVHD的发生在降低复发率以及改善DFS和OS方面具有重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验